Healthcare / BiotechnologyNasdaqGS
$27.05
-1.17 (-4.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-178.4M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-100.0%
↓Gross Margin
89.5%
↑Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
+9.2%
FCF CAGR
—
FCF margin
-1108.2%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.1M · net income $-199.0M · FCF $-178.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $16.1M | $16.1M | $27.1M | $15.8M | $106.5M | — | — | — | — | $13.1M | $25.1M | $10.6M | $6.1M |
| Net Income | $-199.0M | $-199.0M | $-239.6M | $-308.5M | $-126.8M | $329.6M | $-125.0M | $-124.2M | $-83.3M | $-79.3M | $-73.4M | $-82.1M | $-49.8M |
| EBITDA | $-116.6M | $-116.6M | $-160.7M | $-253.1M | $-108.0M | $317.9M | $-114.8M | $-114.5M | $-75.8M | $-63.8M | — | — | — |
| EPS | -3.46 | -3.46 | -4.92 | -6.47 | -2.71 | 7.04 | -2.81 | -3.11 | — | — | — | — | — |
| Gross Margin | 89.5% | 89.5% | 32.4% | 14.0% | 96.9% | — | — | — | — | — | — | — | — |
| Operating Margin | -1166.8% | -1166.8% | -671.8% | -1783.0% | -135.5% | — | — | — | — | -544.3% | -286.7% | -672.6% | -874.2% |
| Net Margin | -1236.0% | -1236.0% | -883.4% | -1947.1% | -119.1% | — | — | — | — | -604.7% | -292.3% | -776.0% | -810.6% |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.32 | 0.32 | -9.78 | 0.67 | 0.30 | 0.17 | 0.15 | 0.11 | 0.20 | 0.22 | 0.31 | 0.11 | — |
| Current Ratio | 10.40 | 10.40 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-178.4M | $-178.4M | $-194.4M | $-153.1M | $-162.7M | $270.5M | $-142.1M | $-104.3M | $-78.4M | $-68.7M | $-87.5M | $-139000.00 | — |
| Returns | |||||||||||||
| ROE | -100.0% | -100.0% | 3547.9% | -148.5% | -26.6% | 55.3% | -51.3% | -38.4% | -46.4% | -88.7% | -115.3% | -64.2% | -116.8% |
| Valuation | |||||||||||||
| P/B | 7.82 | 7.82 | — | 1.51 | 2.26 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | -40.6% | -40.6% | 71.2% | -85.1% | — | — | — | — | — | -47.8% | 137.3% | 72.3% | — |
| EPS Growth | 29.7% | 29.7% | 24.0% | -138.7% | — | 350.5% | 9.6% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+86.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.92 → -3.46
Residual
+86.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.